Motif Bio – antibiotics against multi-drug resistant bacteria

Motif Bio is a biopharma company specialized in developing novel antibiotics against serious and life-threatening infections caused by multi-drug resistant bacteria.

Motif Bio – antibiotics against multi-drug resistant bacteria

Motif Bio

The discovery of new antibiotics against multi-drug resistant bacteria is urgent, as it’s estimated that within five to ten years, routine surgeries such as knee replacements, caesarian section or cardiac catheterization would be impossible without effective antibiotics. One of the biggest threats comes from methicillin‐resistant staphylococcus aureus (MRSA), a leading cause of hospital‐acquired infections and a growing cause of infections in healthy people. Motif Bio is fully dedicated to develop new best‐in‐class antibiotics, each targeting different and unique mechanisms of action to be effective against bacteria that are resistant to most currently available antibiotics. Motif Bio has a lead antibiotic candidate called Iclaprim. Iclaprim is a potential novel antibiotic designed to be effective against bacteria resistant against trimethoprim. Iclaprim is a dihydrofolate reductase (DHFR) inhibitor. Iclaprim exhibits potent activity against Gram-positive bacteria, including methicillin sensitive staphylococci (MSSA) and methicillin resistant staphylococci (MRSA). Based on Iclaprim and other lead compounds, Motif Bio will establish a proprietary lead series to identify DHFR inhibitor effective against a broad spectrum of gram positive bacteria, including those resistant to currently available antibiotics. DHFR inhibitor compounds are known to have rapid analogue synthesis and lead optimization to improve biological and physical properties. This MTF-001 preclinical program aims to bring to the market a novel antibiotic that can be administered by injection or taken orally.

Motif Bio’s team members are already the named inventors on over 160 US‐issued patents. Management Team is composed by Graham Lumsden, Robert Bertoldi and David Huang. Board of Directors is composed by Richard Morgan, Graham Lumsden, Robert Bertoldi, Bruce Williams, Mary Lake Polan, John Stakes, Zaki Hosny, Charlotta Ginman and Jonathan Gold. Motif Bio is positioned to rapidly identify and commercialize novel antibiotics, and Motif Bio’s lead antibiotic candidates could be ready for commercialization as early as 2018.

More about Motif Bio:

Motif Bio – novel antibiotics – multi-drug resistant bacteria – antibiotics against multi-drug resistant bacteria – methicillin‐resistant staphylococcus aureus – MRSA – hospital‐acquired infections – Iclaprim – trimethoprim – dihydrofolate reductase inhibitor – DHFR – MTF-001

Motif Bio – novel antibiotic – multi-drug resistant bacteria – multi drug resistant bacteria – antibiotic against multi-drug resistant bacteria – methicillin resistant staphylococcus aureus – MRSA – hospital‐acquired infection – Iclaprim – trimethoprim – dihydrofolate reductase inhibitors – DHFR inhibitor – gram-positive bacteria – methicillin sensitive staphylococci – MSSA – methicillin resistant staphylococci – MRSA – MTF-001 – MTF001 – Graham Lumsden – Robert Bertoldi – David Huang – Richard Morgan – Graham Lumsden – Robert Bertoldi – Bruce Williams – Mary Lake Polan – John Stakes – Zaki Hosny – Charlotta Ginman – Jonathan Gold